Search Results - "OSMANOV, Evgenii A"

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial by Coiffier, Bertrand, Prof, Osmanov, Evgenii A, Prof, Hong, Xiaonan, Prof, Scheliga, Adriana, MD, Mayer, Jiri, Prof, Offner, Fritz, Prof, Rule, Simon, MD, Teixeira, Adriana, MD, Walewski, Jan, Prof, de Vos, Sven, MD, Crump, Michael, Prof, Shpilberg, Ofer, Prof, Esseltine, Dixie-Lee, MD, Zhu, Eugene, PhD, Enny, Christopher, BS, Theocharous, Panteli, PhD, van de Velde, Helgi, MD, Elsayed, Yusri A, MD, Zinzani, Pier Luigi, Prof

“…Summary Background Bortezomib and rituximab have shown additive activity in preclinical models of lymphoma, and have been shown to be active and generally well…”
Get full text

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib―Rituximab Versus Rituximab by COIFFIER, Bertrand, WEIMIN LI, SCHAFFER, Michael E, OSMANOV, Evgenii A, XIAONAN HONG, SCHELIGA, Adriana, MAYER, Jiri, OFFNER, Fritz, RULE, Simon, TEIXEIRA, Adriana, ROMEJKO-JAROSINSKA, Joanna, DE VOS, Sven, HENITZ, Erin D, CRUMP, Michael, SHPILBERG, Ofer, ZINZANI, Pier Luigi, CAKANA, Andrew, ESSELTINE, Dixie-Lee, MULLIGAN, George, RICCI, Deborah, KARKERA, Jayaprakash D, FAVIS, Reyna, GAFFNEY, Dana, SHAPIRO, Alice, THEOCHAROUS, Panteli, ELSAYED, Yusri A, VAN DE VELDE, Helgi

“…Identify subgroups of patients with relapsed/refractory follicular lymphoma deriving substantial progression-free survival (PFS) benefit with…”
Get full text

Multiple myeloma by Mendeleeva, Larisa P., Votiakova, Olga M., Rekhtina, Irina G., Osmanov, Evgenii A., Poddubnaya, Irina V., Grivtsova, Liudmila Iu, Falaleeva, Natalia A., Baikov, Vadim V., Kovrigina, Alla M., Nevol’skikh, Aleksei A., Ivanov, Sergei A., Khailova, Zhanna V., Gevorkian, Tigran G.

“…Multiple myeloma…”
Get full text

Solitary (extramedullary) plasmocytoma. Clinical recommendations by Falaleeva, Natal’ia A., Terekhova, Alena Iu, Ptushkin, Vadim V., Osmanov, Evgenii A., Poddubnaya, Irina V., Nevol’skikh, Aleksei A., Ivanov, Sergei A., Khailova, Zhanna V., Gevorkian, Tigran G.

“…Solitary (extramedullary) plasmocytoma. Clinical recommendations…”
Get full text

Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study by Robak, Tadeusz, Huang, Huiqiang, Jin, Jie, Zhu, Jun, Liu, Ting, Samoilova, Olga S, Pylypenko, Halyna, Verhoef, Gregor, Siritanaratkul, Noppadol, Osmanov, Evgenii A, Alexeeva, Julia, Pereira, Juliana, Mayer, Jiri, Hong, Xiaonan, Maeda, Yoshiharu, Pei, Lixia, Rooney, Brendan, van de Velde, Helgi, Cavalli, Franco

“…Background: The phase 3, randomized LYM-3002 study compared VR-CAP (n=243) vs R-CHOP (n=244) as frontline therapy in newly diagnosed MCL pts who were…”
Get full text

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study by Coiffier, Bertrand, Li, Weimin, Henitz, Erin D, Karkera, J.D., Favis, Reyna, Gaffney, Dana, Shapiro, Alice, Theocharous, Panteli, Elsayed, Yusri A, van de Velde, Helgi, Osmanov, Evgenii A, Hong, Xiaonan, Scheliga, Adriana, Offner, Fritz C., Rule, Simon, Teixeira, Adriana C, Walewski, Jan, de Vos, Sven, Crump, Michael, Shpilberg, Ofer, Zinzani, Pier Luigi, Cakana, Andrew Z, Esseltine, Dixie-Lee, Mulligan, George, Ricci, Deborah S

“…Abstract 265 Treatment goals in patients with relapsed FL are to prolong PFS and improve overall survival (OS). To optimize treatment for individual patients,…”
Get full text